A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Sep 2027
    • Eligibility criteria expanded, about 23 words
  2. Study title expanded, about 7 wordsv7
  3. Eligibility criteria shortened, about 43 wordsv6
  4. Enrollment target: 100 to 200
    • Study sites revised (7)
    • Eligibility criteria expanded, about 1 word
    v5
  5. Primary endpoint revised
    • Secondary endpoints shortened, about 7 words
    • Site contacts updated at 7 of 7 sites
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria expanded, about 25 wordsv3
  2. Site contacts updated at 7 of 7 sitesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.
Trial Details
NCT Number NCT06055894
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: HealthTree Foundation
Conditions
(from sponsor)		 Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Related terms Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov